Bliss GVS Pharma Limited announced its Q1FY21 results on Aug 20, 2020. Consolidated net revenue of Bliss GVS Pharma Limited in Q1FY21 stood at Rs129.55cr, which declined by 38.76% yoy from Rs211.53cr in Q1FY20.
EBITDA stood at Rs19.48cr in Q1FY21 that decreased by 60.21% yoy. For Q1FY20, it had posted EBITDA of Rs48.96cr. EBITDA margin as of Q1FY21 was at 15.04% that declined by 8.11% yoy against the same quarter, the previous year.
The consolidated net profit in Q1FY21 came in at Rs16.65cr which declined by 50.09%, as compared to Q1FY20, when it had reported Rs33.36cr. The net profit margin in Q1FY21 came in at 12.85% which declined by 2.92% yoy. The net profit margin for Q1FY20 was at 15.77%.
Share price of company closed at Rs132.6 up by 0.11% on BSE.
|
Particulars |
Q1FY21 (Rs in cr) |
Q1FY20 (Rs in cr) |
% VAR |
|
Net Revenue |
129.55 |
211.53 |
-38.76 |
|
Operating Profit |
19.48 |
48.96 |
-60.21 |
|
Net Profit |
16.65 |
33.36 |
-50.09 |
|
EBITDAM% |
15.04 |
23.15 |
-8.11 |
|
PATM% |
12.85 |
15.77 |
-2.92 |
Related Tags:
